Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:50:43.693Z.
Calculation as of: 2026-10-06T14:50:43.693Z.
Quote observation: 2026-10-06T14:50:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 465112d98a6c82939a581bc37d9e1b887570666ec45509b145499b9afd19c223
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$56.60M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aldeyra The (ALDX) | $57.26M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.48M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $58.51M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $56.60M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $59.36M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.51M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $54.74M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.30M | N/A | 108.20x | 108.20x | 108.20x |
| ImageneBio Inc (IMA)vs › | $53.63M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
